MYCAMINE DIN 02311054
Status: Cancelled Post Market
Holder: SANDOZ CANADA INCORPORATED
Molecule: MICAFUNGIN SODIUM
Available to quote
Health Canada record
| Active ingredient(s) | MICAFUNGIN SODIUM 100 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AX05 MICAFUNGIN |
| Original market date | 17-Dec-2009 |
| Current status date | 31-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MICAFUNGIN SODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02568179 | MICAFUNGIN FOR INJECTION, USP | BIOCON PHARMA LIMITED | Powder For Solution | MICAFUNGIN SODIUM 50 MG | Approved |
| 02568195 | MICAFUNGIN FOR INJECTION, USP | BIOCON PHARMA LIMITED | Powder For Solution | MICAFUNGIN SODIUM 100 MG | Approved |
| 02532344 | MICAFUNGIN SODIUM FOR INJECTION | HIKMA CANADA LIMITED | Powder For Solution | MICAFUNGIN SODIUM 50 MG | Marketed |
| 02532360 | MICAFUNGIN SODIUM FOR INJECTION | HIKMA CANADA LIMITED | Powder For Solution | MICAFUNGIN SODIUM 100 MG | Marketed |
| 02294222 | MYCAMINE | SANDOZ CANADA INCORPORATED | Powder For Solution | MICAFUNGIN SODIUM 50 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35049 | 2025-03-20 | New Drug Submission (NDS) | Administrative: Change in product ownership |
| 9556 | 2008-05-21 | Supplement to a New Drug Submission (SNDS) | NEW DOSAGE FORM |
International API supply for MICAFUNGIN SODIUM
12 active FDA Drug Master Files.
Request a quote for MYCAMINE